Related Experiment Video
Updated: May 15, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Should non-inferiority drug trials be banned altogether?
Grace Wangge1, Olaf H Klungel, Kit C B Roes
1Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, PO Box 80082, 3508TB Utrecht, The Netherlands.
Abstract:
Non-inferiority (NI) trials can be used in a situation when a new drug is expected to have a similar efficacy to its comparator but can offer other advantages over the existing drug, such as a more convenient method of administration or fewer side effects. Here, we discuss the advantages and disadvantages of NI trials from an ethical, methodological and regulatory perspective. We suggest that such trials should be designed to address simultaneously the objective of showing NI with regard to drug efficacy and the objective of establishing superiority of the additional advantages of a drug over its active comparator.
Related Concept Videos
Drug Regulation
Bioequivalence studies: Biowaivers
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
